Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)

被引：12
|
作者：
Johnson, B. [1 ]
Miller, V. [2 ]
Amler, L. [3 ]
Stern, H. [3 ]
Soh, C. [3 ]
O'Connor, P. [3 ]
Kabbinavar, F. [4 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] Genentech Inc, San Francisco, CA 94080 USA
[4] Univ Calif Los Angeles, Los Angeles, CA USA
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 03期
关键词：
D O I：
10.1016/S1359-6349(09)72037-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：5 / 6
页数：2
相关论文
共 50 条
  • [31] Randomized, double-blind, placebo-controlled trial of evofosfamide (Evo) and pemetrexed (Perm) in advanced non-squamous non-small cell lung cancer (n-s NSCLC).
    Csoszi, Tibor
    Goldman, Jonathan Wade
    Szilasi, Maria
    Von Pawel, Joachim
    Novello, Silvia
    Carter, Corey Allan
    Ciuleanu, Tudor-Eliade
    Del Conte, Alessandro
    Chatta, Gurkamal
    Schenker, Michael
    Robert, Francisco
    Orlov, Sergey
    Zajda, Katarzyna
    De Marinis, Filippo
    Bennett, Charles L.
    Kroll, Stew
    Pearce, Tillman E.
    Belani, Chandra
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [32] Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST)
    Natale, R. B.
    Thongprasert, S.
    Greco, F. A.
    Thomas, M.
    Tsai, C. M.
    Sunpaweravong, P.
    Ferry, D.
    Langmuir, P.
    Rowbottom, J. A.
    Goss, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] Safety of bevacizumab (B) and erlotinib (E) therapy in patients (pts) with treated brain metastases (mets) in the phase III, placebo (P)-controlled, randomized BeTa trial for pts with advanced non-small cell lung cancer (NSCLC) after failure of standard first-line chemotherapy
    Otterson, G. A.
    O'Connor, P. G.
    Lin, M.
    Herbst, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] A phase II study of erlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small cell lung cancer (NSCLC)
    Groen, H. J.
    Smit, E. F.
    Dingemans, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [35] FAST-ACT: A phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC)
    Lee, J. S.
    Ignacio, J.
    Yu, C.
    Zhou, C.
    Wu, Y.
    Chen, Y.
    Zhang, L.
    Jin, K.
    Johnston, M.
    Mok, T. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study
    Boyer, Michael
    Hui, Rina
    Urban, Damien
    Clingan, Philip
    Su, Wu-Chou
    Devaux, Celine
    Gadgeel, Shirish
    Garassino, Marina
    Leopold, Lance
    Daniel, Jeannie
    Munteanu, Mihaela C.
    Samkari, Ayman
    Luo, Yiwen
    Abreu, Delvys Rodriguez
    BMC CANCER, 2024, 23 (SUPPL 1)
  • [37] A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)
    Groen, H. J. M.
    Socinski, M. A.
    Grossi, F.
    Juhasz, E.
    Gridelli, C.
    Baas, P.
    Butts, C. A.
    Chmielowska, E.
    Usari, T.
    Selaru, P.
    Harmon, C.
    Williams, J. A.
    Gao, F.
    Tye, L.
    Chao, R. C.
    Blumenschein, G. R.
    ANNALS OF ONCOLOGY, 2013, 24 (09) : 2382 - 2389
  • [38] Randomized Double-Blind Placebo-Controlled Trial of Thalidomide in Combination With Gemcitabine and Carboplatin in Advanced Non-Small-Cell Lung Cancer
    Lee, Siow Ming
    Rudd, Robin
    Woll, Penella J.
    Ottensmeier, Christian
    Gilligan, David
    Price, Allan
    Spiro, Stephen
    Gower, Nicole
    Jitlal, Mark
    Hackshaw, Allan
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (31) : 5248 - 5254
  • [39] BIOMARKER ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF ERLOTINIB WITH AND WITHOUT ENTINOSTAT, A CLASS 1 ISOFORM SELECTIVE HISTONE DEACETYLASE INHIBITOR (HDAC) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC; ENCORE-401)
    Jotte, Robert
    Witta, Samir
    Neubauer, Marcus
    Spira, Alexander
    Ruxer, Robert
    Konduri, Kartik
    Hirsch, Fred R.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S607 - S608
  • [40] Phase II trial of erlotinib maintenance therapy after platinun-based chemotherapy in advanced non-small cell lung cancer (NSCLC)
    Cobo, M.
    Martinez, J.
    Montesa, A.
    Gil-Calle, S.
    Villar-Chamorro, E.
    Ales, I.
    Gutierrez, V.
    Duran, G.
    Carabantes-Ocon, F.
    Benavides, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345